Analyzing Arcadia Biosciences (NASDAQ:RKDA) and Grown Rogue International (OTCMKTS:GRUSF)

Grown Rogue International (OTCMKTS:GRUSF) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Grown Rogue International and Arcadia Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grown Rogue International	N/A	N/A	N/A
Arcadia Biosciences	-129.74%	-84.27%	-55.17%

Earnings and Valuation

This table compares Grown Rogue International and Arcadia Biosciences’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grown Rogue International	$23.35 million	5.35	-$130,000.00	$0.01	60.00
Arcadia Biosciences	$5.33 million	0.68	-$13.98 million	($5.16)	-0.52

Grown Rogue International has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Grown Rogue International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

9.3% of Grown Rogue International shares are owned by institutional investors. Comparatively, 17.7% of Arcadia Biosciences shares are owned by institutional investors. 23.2% of Grown Rogue International shares are owned by insiders. Comparatively, 1.8% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Grown Rogue International and Arcadia Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grown Rogue International	0	0	0	0	N/A
Arcadia Biosciences	0	0	1	1	3.50

Arcadia Biosciences has a consensus price target of $6.00, indicating a potential upside of 123.88%. Given Arcadia Biosciences’ higher probable upside, analysts clearly believe Arcadia Biosciences is more favorable than Grown Rogue International.

Summary

Grown Rogue International beats Arcadia Biosciences on 9 of the 13 factors compared between the two stocks.

About Grown Rogue International

Grown Rogue International Inc., together with its subsidiaries, produces and sells cannabis products in the United States. It offers a range of cultivars for consumers, such as indicas, sativas, and hybrids; strain-specific prepackaged flowers; and pre-roll pack products, as well as provides consulting services. The company sells its products through direct-to-retail delivery and third-party delivery, wholesalers, and processors. Grown Rogue International Inc. is headquartered in Medford, Oregon.

About Arcadia Biosciences

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.